Welcome to our dedicated page for Mural Oncology plc news (Ticker: $MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mural Oncology plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mural Oncology plc's position in the market.
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizumab. Nemvaleukin showed promising pharmacodynamic effects, such as expansion of immune-stimulating CD8+ T cells and NK cells, with minimal expansion of immunosuppressive Tregs, and no new safety issues.
Preliminary data from ARTISTRY-6 cohorts are expected in 2025.
Mural Oncology (Nasdaq: MURA) announced Q1 2024 financial results and a business update. Key highlights include ongoing clinical trials for nemvaleukin alfa in ovarian cancer and melanoma, with readouts expected in 1H 2025. Mural is also evaluating a new, less frequent IV dose of nemvaleukin. Preclinical data on IL-18 and IL-12 therapies were presented in April 2024, with candidate nominations anticipated by year-end.
Financially, Mural reported a net loss of $30.9 million, improved from $46.5 million YoY. Cash reserves stand at $231.7 million, expected to fund operations into Q4 2025. R&D expenses decreased to $26.9 million, while G&A expenses rose to $7.2 million, reflecting standalone public company costs.
Mural Oncology plc announced the granting of non-statutory stock options and restricted stock units to three newly hired employees as inducement material. The stock options have an exercise price of $3.78 per share, with a ten-year term and vesting over four years. The restricted stock units also vest over four years, 25% per year, subject to continued service with the Company.